CinCor is a clinical-stage biopharmaceutical company focused on developing our lead clinical candidate, baxdrostat (CIN-107), for the treatment of hypertension and other cardio-renal diseases. Baxdrostat (CIN-107) is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. Baxdrostat (CIN-107) has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure.
We are evaluating the efficacy and safety profile of baxdrostat (CIN-107) as a potential treatment for the broader hypertensive population, including different subpopulations of hypertensive patients who have not achieved blood pressure control despite treatment. We are conducting a Phase 2 clinical trial, which we refer to as our BrigHtn trial, of baxdrostat (CIN-107) in patients whose blood pressure is not controlled despite treatment with three antihypertensive agents, including a diuretic, which is referred to as treatment resistant hypertension, or rHTN. We have recently initiated a separate Phase 2 clinical trial, which we refer to as our HALO trial, in patients with whose blood pressure is not controlled despite treatment with one or more antihypertensive agent, which is referred to as uncontrolled hypertension, or uHTN.
In addition to hypertension, we are developing CIN-107 for the treatment of primary aldosteronism, or PA, and we are exploring its utility in ameliorating complications of chronic kidney disease, or CKD. In 2021 we initiated a Phase 2 clinical trial of CIN-107 in patients with confirmed PA, which we refer to as our spark-PA trial, and, in 2022, have also initiated a Phase 2 clinical trial in patients with CKD who have uncontrolled blood pressure, which we refer to as our FigHtn-CKD trial.
The people behind CinCor Pharma are not only experienced, they’re phenomenal.
Marc de Garidel
Marc de Garidel has served as our Chief Executive Officer and a member of our board of directors since July 2021. Mr. de Garidel serves on the board of directors of Claris Biotherapeutics, Inc. Prior to September 2020, Mr. de Garidel served as the Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2018 until their acquisition by Novo Nordisk A/S in August 2020. Mr. de Garidel also served as the Chief Executive Officer of Ipsen SA from November 2010 to July 2016, and has served as the chairman of Ipsen’s board of directors since November 2010. Mr. de Garidel started his career at Eli Lilly & Co and then served 15 years in multiple growing responsibility roles at Amgen in the US and Europe.
EVP, CFO and CBDO
Terry Coelho has served as our Executive Vice President, Chief Financial Officer and Chief Business Development Officer since November 2021. Previously, Ms. Coelho served as the Executive Vice President, Chief Financial Officer and Treasurer of BioDelivery Sciences International, Inc. from January 2019 to October 2021 and as Chief Financial Officer and Treasurer at Balchem Corporation from October 2017 to October 2018. She also held Chief Financial Officer and Chief Operating Officer roles for Diversey, Inc., and for Diversey Care, a division of Sealed Air Corporation, from October 2014 through September 2017. Previously, Ms. Coelho held senior finance leadership roles with Novartis Pharmaceuticals from 2007 through 2014, as well as roles of increasing responsibility in both finance and general management throughout her twenty year career with Mars, Incorporated. Terry has served on the board of directors for First Wave BioPharma since August 2021.
Catherine Pearce, DHSc
COO & co-founder
Catherine Pearce, M.B.A., D.HSc., co-founded our company in 2018 and has served as our Chief Operating Officer since May 2019. Previously, Ms. Pearce served as both the Chief Operating Officer of CinRx and the vice president, strategic alliances at Medpace from September 2015 until August 2021. Ms. Pearce also served as the Vice President, Research and Development at Teva Pharmaceutical Industries Ltd. from April 2013 until September 2015.
Mason W. Freeman, MD
Since joining CinCor in August 2021, Mason Freeman, M.D., initially served as our Executive Vice President, Clinical Development and, as of March 2022, serves as our Chief Medical Officer. He has also served as a member of our scientific advisory board since June 2019. Additionally, Dr. Freeman serves as a Venture Partner at 5AM Venture Management, LLC, a position he has held since May 2008, as well as the Director of the Massachusetts General Hospital’s Translational Research Center. Previously, Dr. Freeman served as a member of the board of directors of scPharmaceuticals Inc. from July 2018 to December 2020 and Crinetics Pharmaceuticals, Inc. from November 2015 to July 2019.
SVP & Head of People, Talent and CultureIda Hatoum has served as our Senior Vice President, Head of People, Talent and Culture since May 2022. Most recently Ms. Hatoum was the Head of Organizational Development and Training at BioDelivery Sciences from 2014 until joining CinCor. She spent the first 10 years of her career with Roche Diagnostics and Astra Zeneca in the cardiovascular space. She quickly escalated into numerous leadership roles and has over 14 years’ experience leading talent development and culture for several organizations as they scaled from early clinical stage to commercialization.
Senior Management Team
Nadege Briancon-Eris, Ph.D.
Senior Director, Program Management
Vice President, CMC and Quality Control
Yuan-Di Halvorsen, Ph.D.
Vice President, Clinical Operations
James Hui, Ph.D.
Vice President, Clinical Pharmacology and Translational Research
Senior Director, Clinical Data Management
Kevin Schutz, PharmD
VP, Regulatory Affairs
Justin Thompson, MS
Vice President, Business Development
James Healy, MD, Ph.D.
David Allison, Ph.D.
Maina Bhaman, MBA
Marc de Garidel
Chief Executive Officer
Jason Pitts, Ph.D.
John F. Thero
June Lee, MD
Scientific Advisory Board
Morris Brown, MD
Professor of Endocrine Hypertension, Queen Mary, UK
Ulrich Granzer, PhD
Granzer Regulatory and Consulting Services
John Kastelein, MD
Emeritus Professor of Medicine at the Academic Medical Center (AMC) of the University of Amsterdam
Suzanne Oparil, MD
Professor of Medicine / Hypertension Program at University of Alabama
Patrick Rossignol, MD
Professor of Therapeutics, Nephrologist and Vascular Medicine Specialist, Université de Lorraine (France)
Philip T. Sager, MD
Former Chair - FDA Cardiovascular and Renal Advisory Committee
Bryan Williams, MD
Chair of Medicine at UCL, National Institute for Health Research Senior Investigator Emeritus (UK)